Suppr超能文献

纯合基因突变导致肺部受累的囊性纤维化:一例报告

Cystic fibrosis caused by homozygous gene mutation leading to pulmonary involvement: a case report.

作者信息

Duan Ji-Peng, Dai Ru-Fen, Ma Wan-Hong, Luo Tian-Shu, Duan Zhi-Zhen, Zhang Xue-Fen, Zhang Yan-Ling, Liu Ming-Wei

机构信息

Department of Respiratory and Critical Care Medicine, People's Hospital of Dali Bai Autonomous Prefecture Dali 671000, Yunnan, China.

Department of Emergency, People's Hospital of Dali Bai Autonomous Prefecture Dali 671000, Yunnan, China.

出版信息

Am J Transl Res. 2025 May 15;17(5):3813-3823. doi: 10.62347/ENOM2926. eCollection 2025.

Abstract

Cystic fibrosis (CF) is an autosomal recessive monogenic disorder caused by mutations in the CF transmembrane conductance regulator () gene, resulting in impaired protein function. Predominantly affecting Caucasians, CF involves multiple organ systems, including the lungs, pancreas, liver, gastrointestinal tract, and reproductive system. In contrast, CF remains rare among Asian populations, particularly within the Chinese demographic. Reported cases in China predominantly feature heterozygous mutations, with no confirmed instances of homozygous mutations. A 15-year-old male presented with a 6-year history of recurrent cough and purulent yellow-green sputum production, without hemoptysis. Whole exome sequencing identified a homozygous mutation, NM_000492.4:c.2290C>T (p.Arg764*), confirming the diagnosis of CF complicated by pulmonary infection. The patient received intravenous cefoperazone/sulbactam (2.25 g every 12 hours) and moxifloxacin (400 mg once daily). Symptomatic improvement was achieved after 2 weeks, and azithromycin was prescribed (three times weekly) upon discharge. This case highlights the importance of considering gene mutations in patients with prolonged respiratory symptoms (recurrent cough and sputum production) and imaging findings indicative of pulmonary CF. Whole exome sequencing is recommended to determine the genetic etiology in such cases and guide targeted management.

摘要

囊性纤维化(CF)是一种常染色体隐性单基因疾病,由囊性纤维化跨膜传导调节因子(CFTR)基因突变引起,导致CFTR蛋白功能受损。CF主要影响白种人,累及多个器官系统,包括肺、胰腺、肝脏、胃肠道和生殖系统。相比之下,CF在亚洲人群中仍然罕见,尤其是在中国人群中。中国报告的病例主要为杂合CFTR基因突变,尚无纯合突变的确诊病例。一名15岁男性有6年反复咳嗽和咳出黄绿脓性痰的病史,无咯血。全外显子组测序确定了一个纯合CFTR基因突变,NM_000492.4:c.2290C>T(p.Arg764*),确诊为CF合并肺部感染。患者接受静脉注射头孢哌酮/舒巴坦(每12小时2.25 g)和莫西沙星(每日一次400 mg)。2周后症状改善,出院时开具阿奇霉素(每周三次)。该病例强调了对于有长期呼吸道症状(反复咳嗽和咳痰)且影像学表现提示肺部CF的患者,考虑CFTR基因突变的重要性。建议进行全外显子组测序以确定此类病例的遗传病因并指导针对性治疗。

相似文献

1
Cystic fibrosis caused by homozygous gene mutation leading to pulmonary involvement: a case report.
Am J Transl Res. 2025 May 15;17(5):3813-3823. doi: 10.62347/ENOM2926. eCollection 2025.
2
Impact of elexacaftor/tezacaftor/ivacaftor on the small airways in cystic fibrosis.
J Bras Pneumol. 2025 Jun 13;51(2):e20240406. doi: 10.36416/1806-3756/e20240406. eCollection 2025.
4
[Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Apr 12;46(4):352-372. doi: 10.3760/cma.j.cn112147-20221214-00971.
5
Diseases Common in Persons With Cystic Fibrosis Among CFTR Heterozygotes.
JAMA Intern Med. 2025 Jun 16. doi: 10.1001/jamainternmed.2025.1853.
6
Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy.
Chest. 2025 Feb;167(2):348-361. doi: 10.1016/j.chest.2024.09.019. Epub 2024 Sep 27.
7
Evolving nutrition therapy in cystic fibrosis: Adapting to the CFTR modulator era.
Nutr Clin Pract. 2025 Aug;40(4):816-828. doi: 10.1002/ncp.11332. Epub 2025 Jun 18.
9
CRISPR for cystic fibrosis: Advances and insights from a systematic review.
Mol Ther. 2025 Jun 17. doi: 10.1016/j.ymthe.2025.06.021.
10
Renal hydatid cyst mimicking malignancy: a case report.
Int J Surg Case Rep. 2025 Jul;132:111506. doi: 10.1016/j.ijscr.2025.111506. Epub 2025 Jun 13.

本文引用的文献

1
Enrichment of rare CFTR variants in Finnish patients with congenital chloride diarrhea.
PLoS One. 2025 Feb 24;20(2):e0318249. doi: 10.1371/journal.pone.0318249. eCollection 2025.
2
Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis.
J Med Chem. 2025 Feb 13;68(3):2255-2300. doi: 10.1021/acs.jmedchem.4c02547. Epub 2025 Jan 30.
3
Current landscape of cystic fibrosis gene therapy.
Front Pharmacol. 2024 Oct 8;15:1476331. doi: 10.3389/fphar.2024.1476331. eCollection 2024.
4
Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.
Eur Respir J. 2025 Jan 30;65(1). doi: 10.1183/13993003.01683-2023. Print 2025 Jan.
5
6
Elexacaftor-Tezacaftor-Ivacaftor Therapy for Chronic Sinus Disease in Cystic Fibrosis.
JAMA Otolaryngol Head Neck Surg. 2023 Dec 1;149(12):1075-1082. doi: 10.1001/jamaoto.2023.2701.
7
Cystic fibrosis: Epidemiology, clinical manifestations, diagnosis and treatment.
Med Clin (Barc). 2023 Nov 10;161(9):389-396. doi: 10.1016/j.medcli.2023.06.006. Epub 2023 Aug 7.
8
Clinical and genetic characteristics of children with cystic fibrosis in Henan China: A single-center retrospective analysis.
Pediatr Pulmonol. 2023 Oct;58(10):2865-2870. doi: 10.1002/ppul.26601. Epub 2023 Jul 21.
9
Cystic Fibrosis: A Review.
JAMA. 2023 Jun 6;329(21):1859-1871. doi: 10.1001/jama.2023.8120.
10
Cystic Fibrosis Modulator Therapies.
Annu Rev Med. 2023 Jan 27;74:413-426. doi: 10.1146/annurev-med-042921-021447. Epub 2022 Aug 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验